中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
17期
114-115,116
,共3页
胰岛素泵%多次皮下注射%胰岛素%2型糖尿病%肺部感染
胰島素泵%多次皮下註射%胰島素%2型糖尿病%肺部感染
이도소빙%다차피하주사%이도소%2형당뇨병%폐부감염
insulin pump%multiple insulin subcutaneous injection%insulin%type 2 diabetes mellitus%pulmonary infection
目的：比较胰岛素泵与多次皮下注射胰岛素治疗2型糖尿病合并肺部感染的临床疗效。方法选取2012年1月至2013年12月医院收治的2型糖尿病合并肺部感染患者102例，随机分为研究组55例和对照组47例。两组患者均给予消炎、吸氧、平喘、吸痰等对症支持治疗肺部感染研究组加用胰岛素泵进行治疗，对照组加用多次皮下注射胰岛素进行治疗。观察两组患者的肺部感染控制疗效，检测治疗前后的炎性因子水平、血糖控制情况以及胰岛素用量，记录不良反应。结果治疗后，研究组肺部感染控制总有效率为94.55%，明显高于对照组为87.23%（ P<0.05）；研究组的炎性因子血清白细胞介素-6、白细胞介素-8、超敏C反应蛋白水平明显低于对照组（ P<0.05）；研究组患者各时间段的血糖水平和胰岛素平均用量均低于对照组（ P<0.05）；研究组发生低血糖5例（9.09%），对照组12例（25.53%），具有统计学差异（ P<0.05），其余不良反应比较无统计学差异（ P＞0.05）。结论胰岛素泵治疗2型糖尿病合并肺部感染的临床疗效好，能显著降低患者的炎性因子水平，有效控制血糖水平，且胰岛素用量少，不良反应发生率低，值得临床推广。
目的：比較胰島素泵與多次皮下註射胰島素治療2型糖尿病閤併肺部感染的臨床療效。方法選取2012年1月至2013年12月醫院收治的2型糖尿病閤併肺部感染患者102例，隨機分為研究組55例和對照組47例。兩組患者均給予消炎、吸氧、平喘、吸痰等對癥支持治療肺部感染研究組加用胰島素泵進行治療，對照組加用多次皮下註射胰島素進行治療。觀察兩組患者的肺部感染控製療效，檢測治療前後的炎性因子水平、血糖控製情況以及胰島素用量，記錄不良反應。結果治療後，研究組肺部感染控製總有效率為94.55%，明顯高于對照組為87.23%（ P<0.05）；研究組的炎性因子血清白細胞介素-6、白細胞介素-8、超敏C反應蛋白水平明顯低于對照組（ P<0.05）；研究組患者各時間段的血糖水平和胰島素平均用量均低于對照組（ P<0.05）；研究組髮生低血糖5例（9.09%），對照組12例（25.53%），具有統計學差異（ P<0.05），其餘不良反應比較無統計學差異（ P＞0.05）。結論胰島素泵治療2型糖尿病閤併肺部感染的臨床療效好，能顯著降低患者的炎性因子水平，有效控製血糖水平，且胰島素用量少，不良反應髮生率低，值得臨床推廣。
목적：비교이도소빙여다차피하주사이도소치료2형당뇨병합병폐부감염적림상료효。방법선취2012년1월지2013년12월의원수치적2형당뇨병합병폐부감염환자102례，수궤분위연구조55례화대조조47례。량조환자균급여소염、흡양、평천、흡담등대증지지치료폐부감염연구조가용이도소빙진행치료，대조조가용다차피하주사이도소진행치료。관찰량조환자적폐부감염공제료효，검측치료전후적염성인자수평、혈당공제정황이급이도소용량，기록불량반응。결과치료후，연구조폐부감염공제총유효솔위94.55%，명현고우대조조위87.23%（ P<0.05）；연구조적염성인자혈청백세포개소-6、백세포개소-8、초민C반응단백수평명현저우대조조（ P<0.05）；연구조환자각시간단적혈당수평화이도소평균용량균저우대조조（ P<0.05）；연구조발생저혈당5례（9.09%），대조조12례（25.53%），구유통계학차이（ P<0.05），기여불량반응비교무통계학차이（ P＞0.05）。결론이도소빙치료2형당뇨병합병폐부감염적림상료효호，능현저강저환자적염성인자수평，유효공제혈당수평，차이도소용량소，불량반응발생솔저，치득림상추엄。
Objective To compare the clinical efficacy of insulin pump and multiple insulin subcutaneous injection for treating type 2 diabetes mellitus ( T2DM ) complicating pulmonary infection. Methods A total of 102 patients with T2DM complicating pulmonary infec-tion in our hospital from January 2012 to December 2013 were selected and randomly divided into the study group ( 55 cases ) and the control group ( 47 cases ) . The two groups were given the symptomatic therapy of anti-inflammatory, oxygen inhalation, relieving asthma, sputum suction and the support therapy for treating pulmonary infection. The study group was added with the insulin pump and the control group was repeatedly given insulin by subcutaneous injection. The clinical efficacy of pulmonary infection was observed in the two groups. The levels of inflammatory cytokines before and after treatment and glycemic control were detected. The dosage of insulin and adverse reactions were recorded. Results The total effective rate of pulmonary infection after treatment in the study group was 94. 55%, which was significantly higher than 87. 23% in the control group, the difference was statistically significant ( P<0. 05 );the lev-els of inflammatory cytokines including serum interleukin-6,interleukin-8,high-sensitivity C-reactive protein in the study group were significantly lower than those in the control group ( P<0. 05 );the blood glucose level at various time periods and the insulin aver-age dosage in the study group were lower than those in the control group ( P<0. 01 );5 cases ( 9. 09%) of hypoglycemia occurred in the study group, while 12 cases ( 25. 53%) occurred in the control group with statistically significant difference between the two groups ( P<0. 05 ) , the occurrence of other adverse reactions had no statistical difference ( P>0. 05 ) . Conclusion Insulin pump has better effect for treating T2DM complicating pulmonary infection, can significantly decrease the levels of inflammatory cytokines, control the blood glucose level more effectively, reduce the dosage of insulin, has the low occurrence rate of adverse reactions and is worthy of clinical promotion.
